مقالمفتوح (مستودع)2026
Future Medicinal Chemistry · مجلد 18 (19) · 2645-2662
Aims This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis.Materials and methods Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound.Results Compound 11 exhibited the highest cytotoxic activity with IC50 values of 6.08, 5.76, 7.94, and 4.64 µM against MCF-7, MDA-MB-231, HepG-2, and HCT-116, respectively, comparable to sorafenib. It showed potent VEGFR-2 inhibition (IC50 = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles.Conclusions Compound 11 represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.
VEGFR-2 inhibitorsanticancer agentstumor angiogenesiscytotoxicity
مقالمفتوح (مستودع)2026
Archiv der Pharmazie · مجلد 359 (9) · e70328-e70328
ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
chromene derivativesVEGFR-2 inhibitorsantiproliferative activitycancer cell lines
مقالوصول مغلق2026
Chemical Papers
VEGFR-2 inhibitorsangiogenesis inhibitionanticancer drug designVEGFR2 phosphorylation
مقالوصول مغلق2026
Journal of Biomolecular Structure and Dynamics · مجلد 44 (16) · 7537-7551
Targeting the immune checkpoint programmed cell death-ligand 1 (PD-L1) faces diverse challenges against pancreatic ductal adenocarcinoma (PDAC), the most common type of cancer-related death. Shedding of PD-L1 from the tumor cell surface by A Disintegrin And Metalloprotease 10 (ADAM10) may impede the function of antitumor immune cells. Understanding the molecular mechanisms behind this interaction is urgently needed. This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics (MD) simulations. Cellular assays validated that ADAM10 interacts with PD-L1 and sheds the PD-L1 from the cell surface, generating soluble PD-L1 (sPD-L1). Concurrently, the docking results identified critical residues and potential contact points, providing strong evidence for a stable and specific interaction between ADAM10 and PD-L1. The molecular dynamics (MD) simulations further confirmed the structural integrity of the ADAM10/PD-L1 complex, predicting its compactness and stability. These results elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage. Future work can leverage these findings to develop potent cancer immunotherapies that inhibit the ADAM10/PD-L1 interaction and the generation of soluble molecules.
ADAM10PD-L1pancreatic ductal adenocarcinomaprotein-protein interaction
مقالوصول مفتوح2026
Sultan Qaboos University medical journal · مجلد 26 (1) · 455-465
Objectives: Breast cancer (BC) is the most common malignancy among women worldwide and represents a significant burden for Yemeni women. Early detection through breast self-examination (BSE) and knowledge of risk factors and symptoms are crucial. This study aimed to assess awareness, knowledge and practice regarding BC risk factors, symptoms and BSE among female healthcare workers (HCWs) in Al-Mukalla, Yemen. Methods: This cross-sectional study was conducted from September to October 2022 at three public hospitals in Al-Mukalla, Yemen. A census sampling approach was used to recruit HCWs. Data were collected using a validated self-administered questionnaire covering breast awareness practices, risk factor awareness, symptom recognition and BSE frequency. Descriptive statistics and logistic regression were used to identify BSE predictors. Results: A total of 151 HCWs were included in this study (response rate = 83.0%). The mean participant age was 30.4 ± 6.1 years; 49.7% were aged 20–29 years. Most participants were unmarried (66.2%), university-educated (57.0%) and doctors (47.0%). Knowledge of hallmark symptoms such as breast masses (90.0%) was high; however, 51.0% misidentified the specific laterality (right upper outer quadrant) of the most common cancer site, rather than the quadrant itself. Regular (monthly) BSE was reported by 71.5% of participants. Multivariable analysis showed that nurses were less likely than doctors to perform BSE (adjusted odds ratio [aOR] = 0.32, 95% confidence interval [CI]: 0.14–0.73; P = 0.007). Diploma holders practised BSE less than university graduates (aOR = 0.38, 95% CI: 0.19–0.78; P = 0.008), while higher BC knowledge independently predicted greater BSE practice (aOR = 2.15, 95% CI: 1.10–4.20; P = 0.025). Conclusion: Despite good symptom awareness, significant knowledge gaps remain regarding risk factors and breast anatomy among female HCWs in Al-Mukalla, Yemen. BSE practice is still suboptimal, influenced by professional role, education level and BC knowledge. Targeted interventions focusing on breast awareness and structured education are urgently required.
breast cancerbreast self-examinationbreast cancer screeningbreast cancer knowledge
مقالوصول مغلق2026
Journal of Computational Biophysics and Chemistry · 1-20
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.
VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
مقالوصول مفتوح2026
Frontiers in Oncology · مجلد 16 · 1777922-1777922
Background Irinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates. Recently, irinotecan-associated hepatotoxicity was a significant concern. Given the limited study in this area, we aimed to identify risk factors associated with irinotecan-induced hepatotoxicity. Methods This is a retrospective cohort study at King Saud University Medical City in Riyadh. The study encompassed all adult cancer patients who received irinotecan treatment between Jun 2017 and December 2023. The clinical records of patients were reviewed to assess factors associated with hepatotoxicity. Time-to-event analyses were performed using time-varying exposure. Results The study includes 229 adult cancer patients who received irinotecan-based treatment. Median age was 58 years, and colorectal cancer was the most diagnosed type of cancer (68.6%). Over a median follow-up of 103 days, the incidence of hepatotoxicity was 19.2% (n=44). In the adjusted analysis, higher baseline AST was associated with an increased hazard of hepatotoxicity (HR = 1.01; 95% CI: 1.01–1.02; p = 0.001). Cumulative irinotecan dose showed an inverse association with hepatotoxicity, with lower hazards observed in the medium cumulative dose group (HR = 0.36, 95% CI: 0.14–0.91, p = 0.031) and high cumulative dose group (HR = 0.06, 95% CI: 0.01–0.48, p = 0.008) compared with the low cumulative dose group. Conclusion In summary, an inverse association was observed between cumulative irinotecan dose and hepatotoxicity. A higher baseline AST was also associated with hepatotoxicity, warranting careful assessment of pretreatment liver enzymes and closer monitoring during the early treatment period. Further studies are needed to validate these findings and investigate additional predictors of irinotecan-related hepatotoxicity.
irinotecanhepatotoxicityrisk factorscumulative dose
مقالوصول مغلق2026
Journal of Molecular Structure · مجلد 1378 · 147274-147274
theobromine derivativesEGFR inhibitorslung cancerA549 cells
مقالوصول مفتوح2026
Annals of Medicine and Surgery · مجلد 88 (7) · 4020-4033
Background: Population screening and therapeutic advances have changed colorectal cancer (CRC) incidence and survival over recent decades, yet important differences exist by anatomic subsite, histology, and population subgroup. This study describes long-term trends in incidence and survival for colon and rectal tumors. Methods: We analyzed 501 094 primary colon and rectal tumor records from the Surveillance, Epidemiology, and End Results (SEER) Incidence database (1975–2022). Age-adjusted rates used the 2000 U.S. standard population. Outcomes were overall survival (OS) and CRC-specific mortality. OS was estimated using Kaplan–Meier methods and compared between groups by log-rank tests. CRC-specific mortality was evaluated using cause-specific Cox regression based on SEER cause-of-death recodes, adjusting for age, sex, race, histology, primary site, and surgery status. Results: Age-adjusted incidence was 48.3 per 100 000. Median OS improved across eras [Era 1 (1975–1994) 3.83 years, Era 2 (1995–2009) 5.58 years, and Era 3 (2010–2022) 6.92 years, all Eras had P value < 0.001). Left- versus right-sided colon cancers and rectal versus colon primaries showed fixed survival differences across eras. Regarding histology, the signet-ring tumors had markedly worse survival, while neuroendocrine/carcinoid tumors showed better long-term survival. In the adjusted Cox model, several colonic subsites showed a higher hazard of CRC-specific death compared to the appendix. Signet-ring cell histology conferred the greatest mortality risk (HR = 2.206, 95% CI 2.113–2.304; P < 0.001). Conclusions: Over a 47-year period, survival in CRC has significantly improved, but outcomes remain influenced by anatomic subsite and histology. These findings confirm that tumor subsite and histology remain important determinants of long-term prognosis in CRC and highlight the need for risk-adapted management strategies, continued population-based surveillance, and ongoing efforts to address disparities in outcomes.
colorectal cancercolon cancerrectal cancerlong-term survival
مقالوصول مغلق2026
Journal of Computational Biophysics and Chemistry · 1-20
The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.
VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells
مقالوصول مغلق2026
Naunyn-Schmiedeberg s Archives of Pharmacology · مجلد 399 (11) · 17665-17675
lupeolenzalutamidebreast cancersynergistic drug combination
مقالوصول مغلق2026
Journal of Pharmaceutical Innovation · مجلد 21 (5)
Rubiaceaephytochemicalsplant metabolomebreast cancer
مقالوصول مفتوح2026
BMC Cancer · مجلد 26 (1)
Niclosamide, an FDA-approved anti-helminthic drug, has attracted attention for its potential to target multiple cancer-related pathways. This study evaluated the chemopreventive effect of niclosamide in a DMBA/TPA-induced mouse model of skin carcinogenesis and explored its mechanisms using integrated biological and network-based approaches. Mice were treated with niclosamide at 15, 30, and 45 mg/kg and compared with healthy, disease, and standard therapy controls. Tissue and serum analyses were conducted to measure markers of inflammation (TNF-α, IL-6, IL-1β), oxidative stress (MDA, SOD, GSH), apoptosis (caspase-3, Bax/Bcl-2), and angiogenesis (VEGF). Niclosamide reduced tumor volume in a dose-dependent manner, suppressed inflammatory cytokines, restored antioxidant levels, activated apoptotic signaling, and downregulated VEGF expression. A protein-protein interaction network was constructed using eleven experimentally relevant genes to identify key regulatory modules. Network topology and enrichment analysis revealed two functional clusters associated with inflammation, apoptosis, and redox homeostasis. Hub genes such as TNF, IL6, CASP3, and GPX1 highlighted potential interactions among pathways affected by niclosamide. Thus, these findings suggest that niclosamide may exert anticancer effects by modulating interconnected pathways related to inflammation, oxidative stress, apoptosis, and angiogenesis, supporting its potential for further investigation as a repurposed therapeutic candidate for skin cancer.
niclosamideskin cancerchemopreventionDMBA/TPA-induced carcinogenesis
مقالمفتوح (مستودع)2026
Journal of King Saud University - Science · مجلد 38 · 3852025-3852025
Lung cancer is the leading cause of cancer-related death in numerous countries worldwide. Given their severe side effects that can impact the patients’ quality of life, the current treatment approaches need more specific targeting to reduce chemotherapeutic toxicities. Cell-based targeted delivery has recently gained momentum as a promising platform for the delivery of anticancer drugs. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical applications, including targeted drug delivery systems. In the current work, the BG of Streptococcus pneumoniae and Klebsiella pneumoniae ghosts were used as potential targeted-delivery agents for treating lung cancer cells. Bacterial ghosts of S. pneumoniae and K. pneumoniae were prepared using the most recent protocol (tween/acid). The doxorubicin (DOX) uploading was optimized by applying the required conditions to maximize loading capacity. We evaluated the DOX-loaded BGs’ antiproliferative and apoptotic effects on two lung cancer cell lines (H69A, A549) and one normal human embryonic kidney cell line (HEK293) in comparison to free BGs and DOX alone. We also tested the sustained release patterns for each formula. We predicted the mechanism of augmenting the actions of both systems by a protein-protein docking study. The preparation of well-formulated ghosts of both bacteria was successful and confirmed. The loading capacity was maximized to 31.2 ± 3.1% (n=3) for S. pneumoniae ghosts (SPG) and 28.8± 2.6% (n=3) for K. pneumoniae ghosts (KPG). The sustained release pattern of both SPG and KPG followed the Higuchi kinetic model, while Free DOX exhibited a rapid release pattern consistent with the first-order kinetic model. The antiproliferative activity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed the superiority of SPG loaded with DOX (SPG-DOX) over all other tested formulae (10.8% viability) on multi-drug-resistant lung cancer cells (H69A). The IC50s of SPG-Dox loaded were one-sixth and one-fifth of the IC50 of the Free DOX in H69A and A549, respectively, indicating more potency. The cell viability was 46.6% upon using Free DOX. In non-small cell lung cancer cells (A549), the SPG-DOX formula also showed superior antiproliferative activity (23.1% viability), as compared to control vehicles. SPG and KPG showed the highest safety toward the normal cell lines (HEK293), with more than 80% of cells surviving. Using H69A cells, KPG-DOX showed superior apoptotic activity (58.2%) over Free DOX, which achieved less than 20% cellular apoptosis. In A549 cells, SPG-DOX showed apoptotic activity of 57.7% compared to Free DOX. (32.5%). The docking study showed a strong binding interaction between a KPG surface protein (4HWM) and the overexpressed non-small cell lung cancer carcinoma receptor, epidermal growth factor receptor kinase domain (EGFR 2ITO), with a binding score (S) for the interaction of -63.94 kcal/mol. The interaction was -61.26 of SPG surface protein (3ZPP) with EGFR. The application of S. pneumoniae and K. pneumoniae BGs loaded with DOX represents a promising targeted drug delivery system for the treatment of lung cancer. The superior potency and safety of both systems warrant further investigation into their preclinical and clinical activities.
bacterial ghostsdoxorubicinStreptococcus pneumoniaeKlebsiella pneumoniae
مقالوصول مغلق2026
Annals of African Medicine
BACKGROUND: Oculoplastic surgery is a valuable subspecialty in the field of ophthalmology due to the combined functional and esthetic outcomes of treatment for the eyelid, orbit, lacrimal system, and periorbital structures. While the emphasis on clinical and cosmetic applications of oculoplastic surgery continues to increase, awareness and structured training in the field remain limited within ophthalmology residency programs in Saudi Arabia. OBJECTIVE: The objective of this study was to assess the knowledge, exposure, and perceived value of oculoplastic surgery among ophthalmology residents in Saudi Arabia. MATERIALS AND METHODS: A cross-sectional survey of 102 Saudi Board of Ophthalmology residents, representing 42.7% of the national population, was conducted. A validated 31-item questionnaire was used to collect data, which were subsequently analyzed using SPSS v26. Descriptive statistics and inferential tests (t-test, ANOVA) were used to investigate associations between sociodemographic variables and participants' knowledge scores. RESULTS: The majority of residents (87.3%) demonstrated a good level of knowledge in oculoplastic surgery, with a mean overall score of 13.55 ± 3.37 out of 20. Residents showed a strong understanding of core procedures (i.e., orbital fracture repair, eyelid removal for skin cancer), but there were essential knowledge gaps (i.e., management of thyroid eye disease, surgical prioritization, etc.). Participants' knowledge scores were statistically significant for region of residence (P = 0.004) and training level (P = 0.020). Residents varied widely in training exposure (1-156 weeks). Although the majority of residents (80.4%) were satisfied with their training, they cited barriers to participation (limited accessibility to consultants and cases). The majority of participants (66.7%) recommended additional training time, with some concern about reduced exposure to other subspecialties. CONCLUSION: The overall baseline level of knowledge regarding oculoplastic surgery among ophthalmology residents in Saudi Arabia was at least good, but specific misconceptions were identified. Improved and standardized exposure across training programs could address these gaps and better prepare residents for multidisciplinary care in oculoplastic surgery.
oculoplastic surgeryophthalmology residencyresident knowledgesubspecialty training